As second-line therapy for PsA and axSpA, no clear treatment-retention benefit at 3 years was seen when swapping to a bDMARD with another MOA.

Juvenile idiopathic arthritis, older age, and concomitant immunomodulation delay the onset of psoriasiform dermatitis in ...

Tumor necrosis factor inhibitor use in patients with IMIDs did not increase the risk of de novo heart failure or worsen existing heart failure.

Large cohort study finds TNF inhibitors linked to lower cancer risk in psoriasis, supporting long-term safety of biologic ...

Tapering TNF inhibitors is safe and maintains low disease activity for 2 years in psoriatic arthritis and axial ...

We came across a bullish thesis on MoonLake Immunotherapeutics on Valueinvestorsclub.com by skimmer610. In this article, we ...

Ankylosing spondylitis (AS) affects women differently than men. Ankylosing spondylitis symptoms in females may be less ...

In moderate to severe Crohn's disease, a network meta-analysis suggested that TNF inhibitor-based therapy was the most ...

The Ulcerative Colitis treatment paradigm is undergoing a dynamic evolution, marked by increasing therapeutic interventions ...